Neonatal and longer term management following substance misuse in pregnancy

Early Human Development

Volumn 89, Issue 11, 2013, Pages 887-892

  Mactier, Helen ^a,b,c  

^a UK   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Buprenorphine; Methadone; Neonatal abstinence syndrome; Neonate; Substance misuse in pregnancy

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE; OPIATE; OPIATE RECEPTOR;

BRAIN DEVELOPMENT; DRUG MISUSE; EVIDENCE BASED PRACTICE; FOLLOW UP; HUMAN; INTRAUTERINE GROWTH RETARDATION; NERVE CELL DIFFERENTIATION; PREGNANCY; PRENATAL EXPOSURE; REVIEW; VISUAL DISORDER; WITHDRAWAL SYNDROME;

BUPRENORPHINE; METHADONE; NEONATAL ABSTINENCE SYNDROME; NEONATE; SUBSTANCE MISUSE IN PREGNANCY;

ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; MOTHERS; NARCOTIC ANTAGONISTS; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SUBSTANCE-RELATED DISORDERS;

EID: 84886298233     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2013.08.024     Document Type: Review

References (31)

1. Farid W.O., Dunlop S.A., Tait R.J., Hulse G.K. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 2008, 6:125-150.
2. McGlone L., Mactier H., Hassan H., Cooper G. In utero drug and alcohol exposure in infants born to mothers prescribed maintenance methadone. Arch Dis Child 2013, [epub 8/7/13 ahead of print].
3. Clearly B.J., Donnelly J.M., Strawbridge J.D., Gallacher P.J., Fahey T., White M.J., et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011, 204:e1-e9.
4. Dryden C., Young D., Hepburn M., Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for health care resources. Br J Obstet Gynaecol 2009, 116:665-671.
5. Minozzi Amato L., Vecchi S., Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008, (2). [Art. No.: CD006318]. 10.1002/14651858.CD006318pub2.
6. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010, 363:2320-2331.
7. Whitham J.N., Spurrier N.J., Sawyer M.G., Baghurst P.A., Taplin J.E., White J.M., et al. The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicol Teratol 2010, 32:280-288.
8. Cleary B.J., Donnelly J., Strawbridge J., Gallacher P.J., Fahey T., Clarke M., et al. Methadone dose and neonatal abstinence syndrome - systematic review and meta-analysis. Addiction 2012, 105:207-284.
9. Doberczak T.M., Kandall S.R., Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993, 81:936-940.
10. Gaalema D.E., Scott T.L., Heil S.H., Coyle M.G., Kaltenbach K., Badger G.J., et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction 2012, 107:53-62.
11. Dryden C., Young D., Campbell N., Mactier H. Postnatal weight loss in substitute methadone-exposed infants - implications for the management of breast-feeding. Arch Dis Child 2012, 97:214-216.
12. Osborn D.A., Jeffery H.E., Cole M.J. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010, 10:CD002059.
13. Agthe A.G., Kim G.R., Mathais K.B., Hendrix C.W., Chavez-Valdez R., Jansson L., et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 2009, 123:849-856.
14. Kraft W.K., Dysart K., Greenspan J.S., Gibson E., Kaltenbach K., Erlich M.E. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011, 106:574-580.
15. Hendrickson R.G., McKeown N.J. Is maternal opioid use hazardous to breast-fed infants?. Clin Toxicol 2012, 50:1-14.
16. Koren G., Cairns J., Chitayat D., Gaedigk A., Leeder S.J. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006, 368:704.
17. Wachman E.M., Hayes M.J., Brown M.S., Paul J., Harvey-Wilkes K., Terrin N., et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2012, 309:1821-1827.
18. Gordon A.G. Immune genetic predictors of neonatal abstinence syndrome in methadone exposed infants. J Paediatr Child Health 2013, 49:77.
19. Parikh R., Hussain T., Holder G., Bhoyar A., Ewer A.K. Maternal methadone therapy increases QTc interval in newborn infants. Arch Dis Child 2011, 96:F141-F143.
20. McGlone L., Hamilton R., McCulloch D.L., et al. Neonatal visual evoked potentials are altered in infants born to mothers prescribed methadone in pregnancy. Pediatrics 2013, 131:e857-e863.
21. L. McGlone, R. Hamilton, J. MacKinnon, M.S. Bradnam, D.L. McCulloch, H. Mactier. Visual outcome in infants born to drug-misusing mothers prescribed methadone in pregnancy, Br J Ophthalmol, in press.
22. Backes C.H., Gardner D., Nankervis C.A., Giannone P.J., Cordero L. Neonatal abstinence syndrome (NAS): tTransitioning methadone treated infants from an inpatient to an outpatient setting. J Perinatol 2012, 32:425-430.
23. Kelly L.E., Rieder M.J., Bridgman-Acker K., Lauwers A., Madadi P., Koren G. Are infants exposed to methadone in utero at an increased risk for mortality?. J Popul Ther Clin Pharmacol 2012, 19:160-165.
24. Spiteri Cornish K., Hrabovsky M., Scott N.W., Myerscough E., Reddy A.R. The short- and long-term effects on the visual system of children following exposure to maternal substance misuse in pregnancy. Am J Ophthalmol 2013, 156:190-194.
25. Hunt R.W., Tzioumi D., Collins E., Jeffery H.E. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008, 84:29-35.
26. Walhovd K.B., Watts R., Amlien I., Woodward L.J. Neural tract development of infants born to methadone-maintained mothers. Pediatr Neurol 2012, 47:1-6.
27. NSW and ACT NAS Epidemiology Group, Oei J.L., Abdel-Latif M.E., Craig F., Kee A., Austin M.P., Lui K., et al. Short-term outcomes of mothers and newborn infants with comorbid psychiatric disorders and drug dependency. Aust N Z J Psychiatry 2009, 43:323-331.
28. Scher M.S., Richardson G.A., Day N.L. Effects of prenatal cocaine/crack and other drug exposure on electroencephalographic sleep studies at birth and one year. Pediatrics 2000, 105:39-48.
29. Levine T.P., Lester B., Lagasse L., Shankaran S., Bada H.S., Bauer C.R., et al. Psychopathology and special education enrolment in children with prenatal cocaine exposure. J Dev Behav Pediatr 2012, 33:337-386.
30. ALSPAC Study Team, Fergusson D.M., Horwood L.J., Northstone K. Avon longitudinal study of pregnancy and childhood. Maternal use of cannabis and pregnancy outcome, BJOG 2002, 109:21-27.
31. Wu C.-S., Jew C.P., Lu H.-C. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Futur Neurol 2011, 6:459-480.